Evidence map›Paper›PMID 42733378›Full record

ReviewProblemy endokrinologii2026

[Growth hormone and fertility: molecular mechanisms and experience of adjuvant therapy in reproductology].

N N Volevodz, M V Vorontsova, D Yu Nevolnikov, O R Grigoryan, S Y Vorotnikova, R K Mikheev

Abstract readReviewEnglish Abstract
In one paragraph

Review in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

N N VolevodzEndocrinology Research Centre; Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky.
M V VorontsovaEndocrinology Research Centre; M. V. Lomonosov Moscow State University.
D Yu NevolnikovM. V. Lomonosov Moscow State University.
O R GrigoryanEndocrinology Research Centre.
S Y VorotnikovaEndocrinology Research Centre.
R K MikheevEndocrinology Research Centre.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are pivotal hormones regulating not only postnatal growth, development, aging, and longevity but also female reproductive function. In clinical practice, GH is widely utilized as an ad juvant therapy to enhance various clinical outcomes in assisted reproductive technology (ART). It is aimed at increasing the yield and quality of oocytes and embryos, as well as improving pregnancy and live birth rates both in the general population and among patients with GH deficiency. Over the past three decades, the roles of GH and IGF-1 in regulating female repro duction have garnered increasing attention, becoming a major focus of research in both endocrinology and reproductive medicine.

Indexed as

FertilityHuman Growth HormoneInsulin-Like Growth Factor IReproductive Techniques, AssistedFemaleHumansPregnancyHuman Growth HormoneInsulin-Like Growth Factor I

Identifiers

PMID42733378
PMCPMC13585290

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.